Document is current
Any future updates will be listed below
-
Authors
Kim, Miriam Y.
Jayasinghe, Reyka
Devenport, Jessica M.
Ritchey, Julie K.
Rettig, Michael P. https://orcid.org/0000-0002-1091-0564
O’Neal, Julie https://orcid.org/0000-0002-4770-8052
Staser, Karl W.
Kennerly, Krista M.
Carter, Alun J.
Gao, Feng
Lee, Byung Ha https://orcid.org/0000-0002-4139-1226
Cooper, Matthew L.
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
-
Funding
Funding for this research was provided by:
Alex's Lemonade Stand Foundation for Childhood Cancer (Young Investigator Award)
Washington University Division of Physician-Scientists Dean’s Scholars Award, Washington University SPORE in Leukemia Developmental Research Award
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R50 CA211466, P50CA171963, R35CA210084)
International Myeloma Society and Paula and Roger Riney Foundation Translational Research Grant
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Children's Discovery Institute (MC-LI-2017-676)
- License Information
-
More Information
Article History
Received: 30 March 2021
Accepted: 23 May 2022
First Online: 13 June 2022
Competing interests
: M.Y.K., K.W.S., J.O., B.H.L., M.L.C., and J.F.D. are creators/inventors of a patent on the use of IL-7 to enhance CAR T cell function. B.H.L. is currently employed by NeoImmuneTech, Inc. M.L.C. is currently employed by and has equity ownership in Wugen. J.F.D. receives research funding from Amphivena Therapeutics, NeoImmuneTech, Macrogenics, Incyte, Bioline Rx; has equity ownership in Magenta Therapeutics, Wugen; consults for Incyte, RiverVest Venture Partners; and is a board member for Cellworks Group, Inc., RiverVest Venture Partners, Magenta Therapeutics. The remaining authors declare no competing interests.
